Advances in PET/CT Application in Urological Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 39
Special Issue Editor
Special Issue Information
Dear Colleagues,
PET CT has become a major feature of the clinical practice of urological tumor diagnosis, staging and treatment.
Particularly, PSMA-PET CT has been gaining increasing importance in the field of prostate cancer (PCa), as its superiority to conventional imaging in detecting PCa and its metastases have been demonstrated. PSMA-PET CT can be offered in different clinical settings, from the primary staging of prostatic cancer to the re-staging in cases of biochemical recurrence or in the management of metastatic diseases.
For this reason, much of the guidelines emphasize the best performance of this diagnostic method, although its impact on clinical outcomes remains to be proven. On the other hand, theranostics is the new frontier of nuclear medicine; PSMA radioligand treatment is now approved in the metastatic stage of prostate cancer, while many ongoing trials are exploring its possible role in less-advanced stages.
Furthermore, several radiotracers have been evaluated for the diagnosis, staging and management of other urological neoplasms, such as urothelial and kidney cancers.
This Special Issue will cover the different areas of the application of PET CT imaging in the overall management of urological neoplasms.
Dr. Marco Roscigno
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- urothelial cancer
- kidney cancer
- diagnosis
- staging
- treatment
- PSMA PET CT
- FDG PET CT
- CAIX imaging
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
